指南与共识流行病学与生物统计新药、器械与细胞基因治疗研发

低收入与中低收入国家新生儿革兰阴性菌脓毒症及WHO经验性抗生素推荐:系统综述与荟萃分析

Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis.
指南 / 共识 · PLoS Med · 2021-09-28

该系统综述与荟萃分析纳入2010年至2021年发表的88项研究、来自19个低中收入国家的10458株革兰阴性菌分离株,评估新生儿脓毒症中革兰阴性菌占比及耐药情况。结果显示革兰阴性菌占新生儿脓毒症的60%(95%CI 55%至65%),对氨基糖苷类和三代头孢菌素耐药率分别达42%至69%和59%至84%,提示WHO现行经验性抗生素推荐可能不再适用。

要点

  • 低中收入国家新生儿脓毒症中革兰阴性菌占比达60%(95%CI 55%至65%)。
  • 克雷伯菌属最常见,占革兰阴性菌脓毒症的38%(95%CI 33%至43%)。
  • 对氨基糖苷类和三代头孢菌素耐药率分别高达42%至69%和59%至84%。

核心结论

  • 革兰阴性菌是低中收入国家新生儿脓毒症的重要病因,对WHO推荐的一线和二线经验性抗生素耐药率显著。
  • 抗菌药物耐药监测应作为制定区域特异性经验性治疗方案的基础。
  • 全球需承诺为新生儿提供可及且有效的抗菌药物。

研究设计与样本

  • 系统综述与荟萃分析,检索2010年1月1日至2021年4月21日发表的研究。
  • 纳入88项研究(4项队列研究、3项随机对照研究、81项横断面研究),共10458株革兰阴性菌分离株,来自19个低中收入国家。
  • 排除小型病例系列、革兰阴性菌分离株少于10株的研究以及多数分离株来自2010年前的研究。

主要发现

  • 革兰阴性菌所致新生儿脓毒症的合并比例为60%(95%CI 55%至65%)。
  • 克雷伯菌属占革兰阴性菌脓毒症的38%(95%CI 33%至43%),为最常见菌属。
  • 亚洲不动杆菌属比例较高,非洲克雷伯菌属比例较高。
  • 对氨基糖苷类耐药率为42%至69%,对三代头孢菌素耐药率为59%至84%。
  • 未发现非洲和亚洲以外的研究。

关键数值与推荐

  • WHO现行经验性抗生素推荐可能不再适用于低中收入国家新生儿革兰阴性菌脓毒症。
  • 经验性治疗方案应基于区域特异性抗菌药物耐药监测数据制定。

临床怎么用

  • 在低中收入国家,新生儿经验性抗生素选择应参考当地革兰阴性菌耐药监测数据。
  • 需重新评估WHO现行一线和二线经验性抗生素推荐在区域层面的适用性。
  • 应加强新生儿抗菌药物耐药监测,以指导区域特异性治疗推荐。

局限性

  • 纳入研究间存在显著异质性。
  • 排除了中高收入国家的研究。
  • 可能存在采样偏倚,多数研究来自三级医院,可能高估革兰阴性菌负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neonatal sepsis is a significant global health issue associated with marked regional disparities in mortality. Antimicrobial resistance (AMR) is a growing concern in Gram-negative organisms, which increasingly predominate in neonatal sepsis, and existing WHO empirical antibiotic recommendations may no longer be appropriate. Previous systematic reviews have been limited to specific low- and middle-income countries. We therefore completed a systematic review and meta-analysis of available data from all low- and lower-middle-income countries (LLMICs) since 2010, with a focus on regional differences in Gram-negative infections and AMR. METHODS AND FINDINGS: All studies published from 1 January 2010 to 21 April 2021 about microbiologically confirmed bloodstream infections or meningitis in neonates and AMR in LLMICs were assessed for eligibility. Small case series, studies with a small number of Gram-negative isolates (<10), and studies with a majority of isolates prior to 2010 were excluded. Main outcomes were pooled proportions of Escherichia coli, Klebsiella, Enterobacter, Pseudomonas, Acinetobacter and AMR. We included 88 studies (4 cohort studies, 3 randomised controlled studies, and 81 cross-sectional studies) comprising 10,458 Gram-negative isolates from 19 LLMICs. No studies were identified outside of Africa and Asia. The estimated pooled proportion of neonatal sepsis caused by Gram-negative organisms was 60% (95% CI 55% to 65%). Klebsiella spp. was the most common, with a pooled proportion of 38% of Gram-negative sepsis (95% CI 33% to 43%). Regional differences were observed, with higher proportions of Acinetobacter spp. in Asia and Klebsiella spp. in Africa. Resistance to aminoglycosides and third-generation cephalosporins ranged from 42% to 69% and from 59% to 84%, respectively. Study limitations include significant heterogeneity among included studies, exclusion of upper-middle-income countries, and potential sampling bias, with the majority of studies from tertiary hospital settings, which may overestimate the burden caused by Gram-negative bacteria. CONCLUSIONS: Gram-negative bacteria are an important cause of neonatal sepsis in LLMICs and are associated with significant rates of resistance to WHO-recommended first- and second-line empirical antibiotics. AMR surveillance should underpin region-specific empirical treatment recommendations. Meanwhile, a significant global commitment to accessible and effective antimicrobials for neonates is required.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Wen SCH, Ezure Y, Rolley L, et al. Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis. PLoS Med. 2021. PMID: 34582466. doi:10.1371/journal.pmed.1003787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。